Neumora Therapeutics Inc.’s stock tumbled 80% Thursday, after the clinical-stage biotech said a late-stage trial of a ...

Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...

Older adults with major depressive disorder (MDD) demonstrate distinct and riskier driving behaviors than those without MDD, ...

The National Institute of Mental Health defines depression, which is also known as clinical depression or major depressive ...

Medically reviewed by Dakari Quimby, PhD Male postpartum depression describes when a new father experiences postpartum ...

—Major depressive disorder and treatment-resistant depression both require high levels of resources—both clinical and economic—across the spectrum of healthcare settings. A new study from ...

Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.

Neumora's KOASTAL-1 study results show navacaprant missed key goals in major depressive disorder. Additional studies and ...

Transcranial magnetic stimulation for alcohol use disorders is under investigation. Research to date suggests TMS could play ...

Neumora Therapeutics (NMRA) crashed after its Phase 3 study for its lead asset navacaprant in major depressive disorder ...

The changing landscape of health care during COVID-19 placed focus on increasing accessibility to mental health resources other than the emergency department (ED), with potential savings of over $ ...

In a statement, Neumora revealed that the KOASTAL-1 study missed its primary endpoint, with navacaprant failing to achieve a ...